Stem Cell Therapies for Neurodegenerative Diseases

Migration, Crosslink

📖

Stem Cell Therapies for Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:20:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-technologies-stem-cells

📖 Wiki Page

technology1273 wordssynced 2026-04-02

Introduction

...

Introduction

Mermaid diagram (expand to render)

Stem cell therapies represent a promising regenerative medicine approach for [neurodegenerative diseases](/diseases/neurodegenerative-disease), offering the potential to replace lost [neurons](/cell-types/neurons), provide neuroprotective support via [BDNF](/proteins/bdnf-protein) and [GDNF](/proteins/gdnf-protein), and modulate [immune responses](/mechanisms/neuroinflammation). Multiple stem cell types are being investigated for conditions including [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), [Huntington's disease](/diseases/huntingtons), and [amyotrophic lateral sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)[@cell2023][@stem2022].

Relationship to Neurodegenerative Diseases

Stem cell therapy targets multiple pathological features across [tauopathies](/mechanisms/tauopathies) and [synucleinopathies](/mechanisms/synucleinopathies). In [Alzheimer's disease](/diseases/alzheimers-disease), stem cells can replace [cholinergic neurons](/cell-types/cholinergic-neurons) lost to [amyloid-beta](/proteins/amyloid-beta) plaque-induced toxicity and [tau](/proteins/tau) neurofibrillary tangle formation in the [hippocampus](/brain-regions/hippocampus). For [Parkinson's disease](/diseases/parkinsons-disease), [dopaminergic neurons](/cell-types/dopaminergic-neurons) in the [substantia nigra](/brain-regions/substantia-nigra) are the primary target for replacement, addressing the loss of [dopamine](/proteins/dopamine)-producing cells that drives motor symptoms. [Huntington's disease](/diseases/huntingtons) involves degeneration of [medium spiny neurons](/cell-types/medium-spiny-neurons) in the [striatum](/brain-regions/striatum), which can be targeted with [iPSC](/therapeutics/ipsc-therapy)-derived cells. In [ALS](/diseases/amyotrophic-lateral-sclerosis), [motor neuron](/cell-types/motor-neurons) replacement addresses the progressive weakness caused by [TDP-43](/proteins/tardbp-protein) pathology and excitotoxicity. Stem cells also modulate [microglial](/cell-types/microglia) activation to reduce [neuroinflammation](/mechanisms/neuroinflammation) across all these diseases.

Types of Stem Cells

1. Embryonic Stem Cells (ESCs)

Source: Inner cell mass of blastocysts
Pluripotency: Can differentiate into all three germ layers including [dopaminergic neurons](/cell-types/dopaminergic-neurons) for [Parkinson's disease](/diseases/parkinsons-disease)
Advantages: Unlimited expansion, full differentiation potential for [hippocampal](/brain-regions/hippocampus) neuron replacement
Concerns: Ethical issues, tumorigenicity risk, immune rejection affecting [basal ganglia](/brain-regions/basal-ganglia) integration

2. Induced Pluripotent Stem Cells (iPSCs)

Source: Reprogrammed adult somatic cells via [OCT4](/proteins/oct4-protein), [SOX2](/proteins/sox2-protein), [KLF4](/proteins/klf4-protein) expression
Pluripotency: Equivalent to ESCs for generating [motor neurons](/cell-types/motor-neurons) in [ALS](/diseases/amyotrophic-lateral-sclerosis)
Advantages: Patient-specific via [CRISPR](/technologies/crispr) gene editing, no ethical concerns, immune-matched for [substantia nigra](/brain-regions/substantia-nigra) transplantation
Challenges: Cost, [manufacturing](/companies/manufacturing), genetic stability affecting [LRRK2](/genes/lrrk2)-associated [Parkinson's disease](/diseases/parkinsons-disease)

3. Mesenchymal Stem Cells (MSCs)

Source: [Bone marrow](/brain-regions/bone-marrow), adipose tissue, [umbilical cord](/brain-regions/umbilical-cord)
Multipotency: Can differentiate into bone, cartilage, fat for [osteoporosis](/diseases/osteoporosis)-related neurodegeneration
Advantages: Immunomodulatory properties via [TGF-beta](/proteins/tgf-beta-protein) secretion, easily obtained for [ALS](/diseases/amyotrophic-lateral-sclerosis) therapy
Applications: Primarily for immunomodulation reducing [microglial](/cell-types/microglia) activation in [Alzheimer's disease](/diseases/alzheimers-disease)

4. Neural Stem Cells (NSCs)

Source: [Fetal brain tissue](/brain-regions/fetal-brain) or [ESC/iPSC](/therapeutics/ipsc-therapy) differentiation in the [subventricular zone](/brain-regions/subventricular-zone)
Lineage restriction: [Neurons](/cell-types/neurons), [astrocytes](/cell-types/astrocytes), [oligodendrocytes](/cell-types/oligodendrocytes)
Advantages: Natural CNS tropism for [hippocampal](/brain-regions/hippocampus) integration, replacement potential in [substantia nigra](/brain-regions/substantia-nigra)
Challenges: Limited expansion, survival in host [brain](/brain-regions/overview) affected by [alpha-synuclein](/proteins/alpha-synuclein) pathology

5. Direct Reprogramming

Method: Converting [fibroblasts](/cell-types/fibroblasts) directly to [dopaminergic neurons](/cell-types/dopaminergic-neurons) via [ASCL1](/genes/ascl1), [BRN2](/genes/brn2), [MYT1L](/genes/myt1l)
Advantages: No pluripotent stage reducing tumorigenicity, patient-specific for [GBA](/genes/gba)-associated [Parkinson's disease](/diseases/parkinsons-disease)
Status: Preclinical development targeting [striatal](/brain-regions/striatum) neurons

Mechanisms of Action

Cell Replacement

Dopaminergic neurons: For [Parkinson's disease](/diseases/parkinsons-disease) targeting [substantia nigra](/brain-regions/substantia-nigra) [pars compacta](/brain-regions/substantia-nigra-pars-compacta)
Cholinergic neurons: For [Alzheimer's disease](/diseases/alzheimers-disease) targeting [basal forebrain](/brain-regions/basal-forebrain) [cholinergic](/cell-types/cholinergic-neurons) degeneration
Medium spiny neurons: For [Huntington's disease](/diseases/huntingtons) targeting [striatal](/brain-regions/striatum) [GABAergic](/cell-types/gabaergic-neurons) loss
Motor neurons: For [ALS](/diseases/amyotrophic-lateral-sclerosis) targeting [spinal cord](/brain-regions/spinal-cord) [corticospinal](/brain-regions/corticospinal-tract) degeneration

Neuroprotection

Growth factor secretion: [BDNF](/proteins/bdnf-protein), [GDNF](/proteins/gdnf-protein), [NGF](/proteins/nerve-growth-factor) for [dopaminergic neuron](/cell-types/dopaminergic-neurons) survival
Anti-inflammatory effects: Reduced [cytokine](/proteins/cytokines) production via [TGF-beta](/proteins/tgf-beta-protein) modulation in [hippocampus](/brain-regions/hippocampus)
Antioxidant properties: Protection from [oxidative stress](/mechanisms/oxidative-stress) via [glutathione](/proteins/glutathione) enhancement
Synaptic support: Maintaining [neuronal connectivity](/mechanisms/synaptic-plasticity) in [cortex](/brain-regions/cerebral-cortex)

Immunomodulation

T cell modulation: Reducing [autoimmune](/mechanisms/autoimmune-encephalitis) responses affecting [substantia nigra](/brain-regions/substantia-nigra)
Microglial regulation: Shifting to [M2 phenotype](/cell-types/m2-microglia) via [IL-10](/proteins/il-10-protein) secretion to reduce [neuroinflammation](/mechanisms/neuroinflammation)
Anti-apoptotic effects: Preventing [neuron death](/mechanisms/neuronal-death) via [Bcl-2](/proteins/bcl-2-protein) pathway activation

Advantages

Potential for cure: Can replace lost neurons

Disease modeling: Patient iPSCs enable disease study

Personalized medicine: Autologous cells reduce rejection risk

Multiple mechanisms: Replace, protect, and modulate

Continuous improvement: Technologies rapidly advancing

Challenges

Survival and integration: Cells often fail to survive and integrate in the [host brain](/brain-regions/overview), particularly in the [toxic](/proteins/alpha-synuclein) environment of [Parkinson's disease](/diseases/parkinsons-disease) [substantia nigra](/brain-regions/substantia-nigra)

Tumorigenicity: Risk of uncontrolled growth in [hippocampus](/brain-regions/hippocampus), especially with [pluripotent cells](/therapeutics/ipsc-therapy) retaining [p53](/proteins/tp53-protein) dysfunction

Immune rejection: Allogeneic cells may be rejected due to [MHC](/proteins/mhc-complex) mismatch in [ALS](/diseases/amyotrophic-lateral-sclerosis) patients

Delivery: Invasive procedures required for CNS delivery to [basal ganglia](/brain-regions/basal-ganglia), requiring precise [stereotactic](/technologies/stereotactic-surgery) targeting

Standardization: Difficult to manufacture consistent [dopaminergic neuron](/cell-types/dopaminergic-neurons) products for [Parkinson's disease](/diseases/parkinsons-disease)

Cost: Extremely expensive to produce patient-specific [iPSC](/therapeutics/ipsc-therapy)-derived cells ([$500K+ per dose](/companies/cost))

Ethical concerns: ESCs face ethical and regulatory hurdles affecting [clinical trials](/clinical-trials/) in [Alzheimer's disease](/diseases/alzheimers-disease)

Long-term effects: Unknown durability of benefits in [tau](/proteins/tau) [neurofibrillary tangle](/mechanisms/tauopathies)-bearing [hippocampus](/brain-regions/hippocampus)

Pathology exposure: Transplanted cells may be affected by [neuroinflammation](/mechanisms/neuroinflammation) and [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) in host tissue

Current Development Stage

Clinical Trials by Disease

Parkinson's Disease

[BlueRock Therapeutics](/companies/bluerock-therapeutics) ([Bayer](/companies/bayer)): Phase I trial with ESC-derived [dopamine neurons](/proteins/dopamine) targeting [substantia nigra](/brain-regions/substantia-nigra)
[International Stem Cell Corporation](/companies/international-stem-cell-corporation): Phase II with parthenogenetic stem cells for [striatal](/brain-regions/striatum) integration
[Multiple hospitals](/institutions/research-hospitals): Various Phase I/II trials worldwide for [dopaminergic neuron](/cell-types/dopaminergic-neurons) transplantation
Status: Early clinical stages; safety signals observed in [basal ganglia](/brain-regions/basal-ganglia)

Alzheimer's Disease

[Longeveron](/companies/longeveron): MSC therapy Phase I/II completed targeting [hippocampal](/brain-regions/hippocampus) [cholinergic](/cell-types/cholinergic-neurons) function
[Multiple](/companies/): Small trials ongoing for [neuroinflammation](/mechanisms/neuroinflammation) modulation via [microglial](/cell-types/microglia) regulation
Challenge: More complex pathology than PD, with [amyloid-beta](/proteins/amyloid-beta) plaques and [tau](/proteins/tau) tangles affecting cell survival

Huntington's Disease

[Neuralstem](/companies/neuralstem): Phase I trial with NSC transplantation targeting [striatal](/brain-regions/striatum) [medium spiny neurons](/cell-types/medium-spiny-neurons)
[Various](/companies/): Multiple early-stage trials for [GABAergic](/cell-types/gabaergic-neurons) neuron replacement
Focus: Replacing [medium spiny neurons](/cell-types/medium-spiny-neurons) in [caudate nucleus](/brain-regions/caudate-nucleus) and [putamen](/brain-regions/putamen)

ALS

[Brainstorm Cell Therapeutics](/companies/brainstorm-cell-therapeutics): Phase III with MSC-NTF cells for [neurotrophic factor](/proteins/gdnf-protein) secretion
[Various](/companies/): Multiple Phase I/II trials via [intrathecal](/techniques/intrathecal-delivery) delivery
Approach: Neuroprotective via [GDNF](/proteins/gdnf-protein) delivery rather than [motor neuron](/cell-types/motor-neurons) replacement

Clinical Trial Landscape

| Disease | Active Trials | Phase | Cell Type |
|---------|--------------|-------|-----------|
| Parkinson's | 15+ | I/II | ESC, iPSC, NSC |
| Alzheimer's | 8+ | I/II | MSC, NSC |
| Huntington's | 5+ | I | NSC |
| ALS | 12+ | I/II/III | MSC, NSC |

Companies Working on Stem Cell Therapies

Major Biotechnology Companies

[BlueRock Therapeutics](/companies/bluerock-therapeutics) ([Bayer](/companies/bayer)): ESC-derived [dopamine neurons](/proteins/dopamine) for [Parkinson's disease](/diseases/parkinsons-disease)
[Brainstorm Cell Therapeutics](/companies/brainstorm-cell-therapeutics): MSC-NTF cells for [ALS](/diseases/amyotrophic-lateral-sclerosis) via [neurotrophic](/proteins/gdnf-protein) support
[Fate Therapeutics](/companies/fate-therapeutics): iPSC-derived NK and T cells for [neuroinflammation](/mechanisms/neuroinflammation) modulation
[Celularity](/companies/celularity): Placental-derived stem cells for [Alzheimer's disease](/diseases/alzheimers-disease) immunotherapy

Pharmaceutical Partners

[Bayer](/companies/bayer): [BlueRock acquisition](/companies/bluerock-therapeutics) for cell therapy targeting [substantia nigra](/brain-regions/substantia-nigra)
[Sumitomo](/companies/sumitomo): [Parkinson's cell therapy](/diseases/parkinsons-disease) programs for [dopaminergic neuron](/cell-types/dopaminergic-neurons) replacement
[Astellas](/companies/astellas): [iPSC](/therapeutics/ipsc-therapy) programs for [CNS disease](/diseases/cns-disease) including [tauopathies](/mechanisms/tauopathies)

Academic Programs

[Harvard/MIT](/institutions/harvard): Multiple [iPSC](/therapeutics/ipsc-therapy) programs for [Alzheimer's disease](/diseases/alzheimers-disease) and [ALS](/diseases/amyotrophic-lateral-sclerosis)
[Stanford](/institutions/stanford): NSC transplantation research for [Parkinson's disease](/diseases/parkinsons-disease) in [substantia nigra](/brain-regions/substantia-nigra)
[University of Wisconsin](/institutions/university-wisconsin): ESC differentiation protocols for [dopaminergic neuron](/cell-types/dopaminergic-neurons) generation

Manufacturing Considerations

Scalable Production

Bioreactor expansion: Large-scale cell culture
Differentiation protocols: Defined, reproducible methods
Quality control: Ensuring consistent product

Storage and Delivery

Cryopreservation: Viability maintenance
Fresh vs. frozen: Logistics considerations
Delivery devices: Specialized implantation tools

Regulatory Pathway

Autologous vs. allogeneic: Different regulatory routes
CMC requirements: Manufacturing complexity
Combination products: Cells with devices

Safety Considerations

Tumorigenicity

Monitoring: Long-term follow-up required
Genetic stability: Ensuring karyotypic normalcy
Purification: Removing undifferentiated cells

Immunogenicity

Autologous cells: Minimal immune concerns
Allogeneic cells: May require immunosuppression
Immunomodulation: Using compatible cell types

Surgical Risks

Intracranial injection: Bleeding, infection
Stereotactic procedures: Precision required
Monitoring: Post-procedure care

Future Directions

Emerging Technologies

3D bioprinting: Creating complex neural tissues
Organoids: Brain organoids for transplantation
Gene editing: Correcting patient iPSCs before移植
Biomaterials: Scaffolds for cell support

Combination Approaches

Stem cells plus gene therapy
Cell therapy plus small molecules
Multiple cell types for complex diseases

Breakthroughs Needed

Improved survival and integration
Reliable functional outcomes
Scalable manufacturing
Cost reduction

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Cell therapy for Parkinson's disease: progress and challenges (Nature Reviews Neurology, 2023) (2023)](https://doi.org/10.1038/s41582-023-00801-4)

[Unknown, Stem cell therapies for neurodegenerative diseases (Cell Stem Cell, 2022) (2022)](https://doi.org/10.1016/j.stem.2022.09.011)

[Unknown, Clinical applications of stem cells in neurology (Brain, 2023) (2023)](https://doi.org/10.1093/brain/awad157)

Pathway Diagram

The following diagram shows the key molecular relationships involving Stem Cell Therapies for Neurodegenerative Diseases discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

technologies-stem-cells

▸Metadataorigin_type: v1_polymorphic_backfill

slug	technologies-stem-cells
kg_node_id	None
entity_type	technology
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-eeab25b35fbf
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'technologies-stem-cells'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

28

Outgoing

38

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Stem Cell Therapies for Neurodegenerative Diseases

Introduction

Introduction

Relationship to Neurodegenerative Diseases

Types of Stem Cells

1. Embryonic Stem Cells (ESCs)

2. Induced Pluripotent Stem Cells (iPSCs)

3. Mesenchymal Stem Cells (MSCs)

4. Neural Stem Cells (NSCs)

5. Direct Reprogramming

Mechanisms of Action

Cell Replacement

Neuroprotection

Immunomodulation

Advantages

Challenges

Current Development Stage

Clinical Trials by Disease

Parkinson's Disease

Alzheimer's Disease

Huntington's Disease

ALS

Clinical Trial Landscape

Companies Working on Stem Cell Therapies

Major Biotechnology Companies

Pharmaceutical Partners

Academic Programs

Manufacturing Considerations

Scalable Production

Storage and Delivery

Regulatory Pathway

Safety Considerations

Tumorigenicity

Immunogenicity

Surgical Risks

Future Directions

Emerging Technologies

Combination Approaches

Breakthroughs Needed

See Also

External Links

References

Pathway Diagram

💬 Discussion